0.30
+13.21%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Alterity Therapeutics
Its shares trade on ASX under the ticker ATH.AX. It has been listed since 27 March 2000. In the fiscal year to 30 June 2025, it reported revenue of A$446,300 and a net loss of A$12.1m.
Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. The company is headquartered in Melbourne, Victoria. The company went IPO on 2000-03-27. The firm is engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's disease, Huntington disease, Parkinson's disease and other neurological disorders. The firm's lead product candidates are PBT2 and PBT434. The firm's lead drug candidate PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. The firm also has advanced a drug candidate for Parkinson's disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing. Its other applications for its therapies include certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease), and a range of orphan neurodegenerative disorders.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 27 Mar 2000
- Employees
- 12
- Website
- pranabio.com ↗
Leadership
Pay as last reported
- Mr. Geoffrey KemplerNon-Executive Chairman of the Board, since 1997A$280,000
- Dr. David StamlerChief Executive OfficerA$1.4m
- Ms. Abby NivenChief Financial Officer, Company Secretary
- Mr. Lawrence GozlanNon-Executive DirectorA$70,000
- Mr. Peter MarksNon-Executive Independent DirectorA$70,000
- Mr. Brian MeltzerNon-Executive Independent DirectorA$70,000
- Ms. Hannah HowlettInvestor Relations, since 2023
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 54
- Environment
- 55
- Social
- 74
- Governance
- 31
- Women in the workforce
- 67%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Alterity Therapeutics Ltd has a strong product portfolio with innovative drug candidates that address neurological diseases.
- The company has a robust pipeline of potential treatments, ensuring future growth and expansion.
- Alterity Therapeutics Ltd has a talented team of researchers and scientists with extensive experience in the pharmaceutical industry.
Weaknesses
- The company is heavily reliant on the success of its drug candidates, with limited diversification in the product portfolio.
- Alterity Therapeutics Ltd may face challenges in securing sufficient funding for clinical trials and research and development activities.
- The company operates in a highly competitive market, which can impact its ability to gain market share.
Opportunities
- The increasing prevalence of neurological diseases presents a significant opportunity for Alterity Therapeutics Ltd to capture a larger market share.
- Advancements in technology and research in the field of neurology create potential for the development of breakthrough treatments.
- Partnerships and collaborations with other pharmaceutical companies or research institutions can provide access to additional resources and expertise.
Threats
- Regulatory challenges and the lengthy approval process for new drugs pose a threat to the timely commercialization of Alterity Therapeutics Ltd's products.
- Competitors in the industry may develop similar or superior drug candidates, limiting the market potential for Alterity Therapeutics Ltd.
- Changes in healthcare policies and reimbursement systems can impact the pricing and market access of the company's products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.